Dosimetric and clinical predictors for radiation-induced esophageal injury.
暂无分享,去创建一个
Lawrence B Marks | Sung-Ja Ahn | Sumin Zhou | L. Marks | D. Hollis | Sumin Zhou | Xiaoli Yu | Daniel Kahn | T. Shafman | Donna Hollis | Timothy D Shafman | Xiaoli Yu | S. Ahn | D. Kahn
[1] C. Hess,et al. Therapeutic outcome and relation of acute and late side effects in the adjuvant radiotherapy of endometrial carcinoma stage I and II. , 1999, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[2] Jeffrey D Bradley,et al. Predictors of radiation-induced esophageal toxicity in patients with non-small-cell lung cancer treated with three-dimensional conformal radiotherapy. , 2003, International journal of radiation oncology, biology, physics.
[3] T. Pajak,et al. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC) , 1995, International journal of radiation oncology, biology, physics.
[4] H. Choy,et al. Esophagitis in combined modality therapy for locally advanced non-small cell lung cancer. , 1999, Seminars in radiation oncology.
[5] L. Marks,et al. High-dose, hyperfractionated, accelerated radiotherapy using a concurrent boost for the treatment of nonsmall cell lung cancer: unusual toxicity and promising early results. , 1996, International journal of radiation oncology, biology, physics.
[6] W. Curran,et al. Predictors of severe esophagitis include use of concurrent chemotherapy, but not the length of irradiated esophagus: a multivariate analysis of patients with lung cancer treated with nonoperative therapy. , 2000, International journal of radiation oncology, biology, physics.
[7] F. Mascarenhas,et al. Acute Secondary Effects in the Esophagus in Patients Undergoing Radiotherapy for Carcinoma of the Lung , 1989, American journal of clinical oncology.
[8] H. Bartelink,et al. Radiotherapy combined with low-dose cis-diammine dichloroplatinum (II) (CDDP) in inoperable nonmetastatic non-small cell lung cancer (NSCLC): a randomized three arm phase II study of the EORTC Lung Cancer and Radiotherapy Cooperative Groups. , 1990, International journal of radiation oncology, biology, physics.
[9] M. Socinski,et al. High-dose conformal radiotherapy for treatment of stage IIIA/IIIB non-small-cell lung cancer: technical issues and results of a phase I/II trial. , 2002, International journal of radiation oncology, biology, physics.
[10] P. Maguire,et al. A new three-dimensional dose distribution reduction scheme for tubular organs. , 2000, Medical physics.
[11] M. Parmar,et al. Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: a randomised multicentre trial , 1997, The Lancet.
[12] H. Athanassiou,et al. Randomized phase III trial of radiation treatment +/- amifostine in patients with advanced-stage lung cancer. , 2001, International journal of radiation oncology, biology, physics.
[13] P. Maguire,et al. 73.6 Gy and beyond: hyperfractionated, accelerated radiotherapy for non-small-cell lung cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] R. Komaki,et al. Response, toxicity, failure patterns, and survival in five Radiation Therapy Oncology Group (RTOG) trials of sequential and/or concurrent chemotherapy and radiotherapy for locally advanced non-small-cell carcinoma of the lung. , 1998, International journal of radiation oncology, biology, physics.
[15] W. Dörr,et al. Consequential late effects in normal tissues. , 2001, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[16] K. Rosenzweig,et al. Elective nodal irradiation in the treatment of non-small-cell lung cancer with three-dimensional conformal radiation therapy. , 2001, International journal of radiation oncology, biology, physics.
[17] H. Beck-Bornholdt,et al. Radiation-induced impairment of urinary bladder function in mice: fine structure of the acute response and consequences on late effects. , 1999, Radiation research.
[18] F. Khuri,et al. Randomized phase III study of chemoradiation with or without amifostine for patients with favorable performance status inoperable stage II-III non-small cell lung cancer: preliminary results. , 2002, Seminars in radiation oncology.
[19] D. Booser,et al. Esophageal complications from combined chemoradiotherapy (cyclophosphamide + Adriamycin + cisplatin + XRT) in the treatment of non-small cell lung cancer. , 1985, International journal of radiation oncology, biology, physics.
[20] G Bentel,et al. Positioning and immobilization of patients undergoing radiation therapy for Hodgkin's disease. , 1991, Medical dosimetry : official journal of the American Association of Medical Dosimetrists.
[21] R J Myerson,et al. Late effects of radiation therapy on the gastrointestinal tract. , 1995, International journal of radiation oncology, biology, physics.
[22] G. Sibley. Radiotherapy for patients with medically inoperable stage I nonsmall cell lung carcinoma , 1998, Cancer.
[23] P. Jacob,et al. Radiation-induced esophageal injury: a spectrum from esophagitis to cancer. , 1990, The American journal of gastroenterology.
[24] D. Ettinger,et al. Randomized phase II chemotherapy and radiotherapy trial for patients with locally advanced inoperable non-small-cell lung cancer: long-term follow-up of RTOG 92-04. , 2002, International journal of radiation oncology, biology, physics.
[25] M. Goitein,et al. Tolerance of normal tissue to therapeutic irradiation. , 1991, International journal of radiation oncology, biology, physics.
[26] P. Lorigan,et al. Fatal pulmonary fibrosis associated with induction chemotherapy with carboplatin and vinorelbine followed by CHART radiotherapy for locally advanced non-small cell lung cancer. , 2002, Clinical oncology (Royal College of Radiologists (Great Britain)).
[27] R. Komaki,et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. , 1999, The New England journal of medicine.
[28] K. Propert,et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. , 1990, The New England journal of medicine.
[29] W. Curran,et al. Final Results of Phase III Trial in Regionally Advanced Unresectable Non-Small Cell Lung Cancer : Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group , 2000 .
[30] R. Clough,et al. Risk of long-term complications after TFG-beta1-guided very-high-dose thoracic radiotherapy. , 2003, International journal of radiation oncology, biology, physics.
[31] P. Maguire,et al. Clinical and dosimetric predictors of radiation-induced esophageal toxicity. , 1999, International journal of radiation oncology, biology, physics.
[32] M. Socinski,et al. Dose‐escalating conformal thoracic radiation therapy with induction and concurrent carboplatin/paclitaxel in unresectable stage IIIA/B nonsmall cell lung carcinoma , 2001, Cancer.